CuraGen's (CRGN) CR011-vcMMAE Phase I/II Trial Meets Efficacy Criteria
More News related to CRGN
- Celldex (CLDX) Closes Acquisition of CuraGen (CRGN)
- Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation
- Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation
- CuraGen's (CRGN) CR011-vcMMAE Phase I/II Trial Meets Efficacy Criteria
- Morning Movers 6/3: TIVO, APPA, CTIC, PMI, SAY, TSRA Higher; VLO, MIND, STLD, CRGN, AET Lower
More News related to Corporate News
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
CuraGen Corporation (Nasdaq: CRGN) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients with advanced breast cancer has met the efficacy criteria for advancement to the second stage of enrollment.
To date, 29 patients have been enrolled in this trial, including 15 in the Phase II portion. Two of the first four evaluable Phase II patients were progression-free at 12 weeks, therefore, as part of the Simon 2-Stage design, the Phase II trial will now advance to the second stage and enroll a total of approximately 25 patients. The principal investigator of the study is Dr. Linda Vahdat, Medical Director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, /Weill Cornell. CuraGen anticipates presenting updated results from this study during the second half of 2009.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
